Research programme: xanthine oxidase inhibitors - Rocket Pharmaceuticals
Alternative Names: AN-260; XO inhibitors - Rocket PharmaceuticalsLatest Information Update: 09 Jan 2018
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure; Rheumatoid arthritis
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 08 Oct 2007 Discontinued - Preclinical for Congestive heart failure in USA (unspecified route)
- 08 Oct 2007 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)